Abstract
Introduction: The worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an extraordinary increase in the number of severe and critically ill patients in a relatively short span of time. Cardiovascular risk factors and outcomes are noted as being key contributing features of many patients who ultimately develop severe illness. As such, laboratory markers for cardiac damage and failure have been described as being elevated in this subset of patients. Hypothesis: The purpose of this meta-analysis is to identify and compare the values of natriuretic peptides in severely ill patient infected with the SARS-CoV-2 compared to those who are identified as being not severe. Methods: PUBMED and Medrxiv were searched through April 15th 2020. The outcome of interest is the difference of BNP or NT-pro BNP in severe versus non-severe Results: We identified 9 eligible retrospective cohort studies that observed a total of 1,575 patients that had their natriuretic peptides measured and who were classified by disease severity. Patients who were identified as having a non-severe status with the SARS-CoV-2 infection had a mean difference of -69.56 (95% CI) [-137.35, -1.77, P =0.04, I2=83%) in B-type natriuretic peptide (BNP) levels compared to those with severe status. Similarly, patients who had their N-terminal-pro BNP (NT-proBNP) levels measures had a mean difference of -518.65 (95% CI) [ -884.90, -152.40, P=0.006, I2=86%) when compared to those whom NT-proBNP levels were measured with severe status. Conclusions: In conclusion, patients infected with the SARS-CoV-2 virus and were classified as severe had higher levels of natriuretic peptides than patients who were classified as not severe.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call